Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


CITED2 attenuates macrophage recruitment concordant with the downregulation of CCL20 in breast cancer cells.

Jayaraman S, Doucet M, Kominsky SL.

Oncol Lett. 2018 Jan;15(1):871-878. doi: 10.3892/ol.2017.7420. Epub 2017 Nov 15.


Down-regulation of CITED2 attenuates breast tumor growth, vessel formation and TGF-β-induced expression of VEGFA.

Jayaraman S, Doucet M, Kominsky SL.

Oncotarget. 2017 Jan 24;8(4):6169-6178. doi: 10.18632/oncotarget.14048.


CITED2 Modulates Breast Cancer Metastatic Ability through Effects on IKKα.

Jayaraman S, Doucet M, Lau WM, Kominsky SL.

Mol Cancer Res. 2016 Aug;14(8):730-9. doi: 10.1158/1541-7786.MCR-16-0081. Epub 2016 May 23.


CCL20/CCR6 Signaling Regulates Bone Mass Accrual in Mice.

Doucet M, Jayaraman S, Swenson E, Tusing B, Weber KL, Kominsky SL.

J Bone Miner Res. 2016 Jul;31(7):1381-90. doi: 10.1002/jbmr.2813. Epub 2016 Mar 11.


Enpp1: a potential facilitator of breast cancer bone metastasis.

Lau WM, Doucet M, Stadel R, Huang D, Weber KL, Kominsky SL.

PLoS One. 2013 Jul 5;8(7):e66752. doi: 10.1371/journal.pone.0066752. Print 2013.


CITED2 modulates estrogen receptor transcriptional activity in breast cancer cells.

Lau WM, Doucet M, Huang D, Weber KL, Kominsky SL.

Biochem Biophys Res Commun. 2013 Jul 26;437(2):261-6. doi: 10.1016/j.bbrc.2013.06.063. Epub 2013 Jun 27.


MIP-1δ activates NFATc1 and enhances osteoclastogenesis: involvement of both PLCγ2 and NFκB signaling.

Weber KL, Doucet M, Shaner A, Hsu N, Huang D, Fogel J, Kominsky SL.

PLoS One. 2012;7(7):e40799. doi: 10.1371/journal.pone.0040799. Epub 2012 Jul 9.


Preclinical and clinical evaluation of intraductally administered agents in early breast cancer.

Stearns V, Mori T, Jacobs LK, Khouri NF, Gabrielson E, Yoshida T, Kominsky SL, Huso DL, Jeter S, Powers P, Tarpinian K, Brown RJ, Lange JR, Rudek MA, Zhang Z, Tsangaris TN, Sukumar S.

Sci Transl Med. 2011 Oct 26;3(106):106ra108. doi: 10.1126/scitranslmed.3002368.


Identification of prospective factors promoting osteotropism in breast cancer: a potential role for CITED2.

Lau WM, Weber KL, Doucet M, Chou YT, Brady K, Kowalski J, Tsai HL, Yang J, Kominsky SL.

Int J Cancer. 2010 Feb 15;126(4):876-84. doi: 10.1002/ijc.24780.


MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1.

Kominsky SL, Doucet M, Thorpe M, Weber KL.

Clin Exp Metastasis. 2008;25(8):865-70. doi: 10.1007/s10585-008-9202-2. Epub 2008 Aug 16.


Macrophage inflammatory protein-1 delta: a novel osteoclast stimulating factor secreted by renal cell carcinoma bone metastasis.

Kominsky SL, Abdelmagid SM, Doucet M, Brady K, Weber KL.

Cancer Res. 2008 Mar 1;68(5):1261-6. doi: 10.1158/0008-5472.CAN-07-6122.


Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis.

Kominsky SL, Tyler B, Sosnowski J, Brady K, Doucet M, Nell D, Smedley JG 3rd, McClane B, Brem H, Sukumar S.

Cancer Res. 2007 Sep 1;67(17):7977-82.


TGF-beta promotes the establishment of renal cell carcinoma bone metastasis.

Kominsky SL, Doucet M, Brady K, Weber KL.

J Bone Miner Res. 2007 Jan;22(1):37-44.


Claudins: emerging targets for cancer therapy.

Kominsky SL.

Expert Rev Mol Med. 2006 Aug 4;8(18):1-11. Review.


A "bone" fide predictor of metastasis? Predicting breast cancer metastasis to bone.

Kominsky SL, Davidson NE.

J Clin Oncol. 2006 May 20;24(15):2227-9. Epub 2006 Apr 24. No abstract available.


Ductal access for prevention and therapy of mammary tumors.

Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Huso D, Baker SD, Barber J, Jaffee E, Reilly RT, Sukumar S.

Cancer Res. 2006 Jan 15;66(2):638-45.


Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung.

Mehrotra J, Vali M, McVeigh M, Kominsky SL, Fackler MJ, Lahti-Domenici J, Polyak K, Sacchi N, Garrett-Mayer E, Argani P, Sukumar S.

Clin Cancer Res. 2004 May 1;10(9):3104-9.


Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S.

Oncogene. 2003 Apr 3;22(13):2021-33.


Superantigen enhanced protection against a weak tumor-specific melanoma antigen: implications for prophylactic vaccination against cancer.

Kominsky SL, Torres BA, Hobeika AC, Lake FA, Johnson HM.

Int J Cancer. 2001 Dec 15;94(6):834-41.


Inhibition of the glioblastoma cell cycle by type I IFNs occurs at both the G1 and S phases and correlates with the upregulation of p21(WAF1/CIP1).

Tanabe T, Kominsky SL, Subramaniam PS, Johnson HM, Torres BA.

J Neurooncol. 2000 Jul;48(3):225-32.


Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.

Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM.

Cancer Res. 2000 Jul 15;60(14):3904-8.


Inhibitory effects of IFN-gamma and acyclovir on the glioblastoma cell cycle.

Kominsky SL, Subramaniam PS, Johnson HM, Torres BA.

J Interferon Cytokine Res. 2000 May;20(5):463-9.


Supplemental Content

Loading ...
Support Center